ニュース

Cellular Intelligence is acquiring STEM-PD, a Phase 2-ready cell therapy, and plans to use AI to accelerate development and manufacturing

Novo Nordisk shuttered its cell therapy unit in October 2025, with assets now moving to new hands.

Novo Nordisk stock jumps 21% in a month after a Q1 beat and stronger GLP-1 demand, but pricing pressure and Eli Lilly rivalry still cloud its 2026 outlook.

Shares in Novo Nordisk (NYSE:NVO) drew a cautious reception from Citi following first-quarter results that beat consensus expectations, with the bank raising its target price but retaining a neutral rating as concerns over portfolio price erosion and long-term obesity market competition outweigh...

Hims & Hers Health (NYSE:HIMS) has launched Labs AI, an AI care agent that provides users with personalized, clinically vetted interpretations of their lab results. The company is also expanding into FDA-approved GLP-1 weight loss medications through partnerships with major pharmaceutical companies, including Novo Nordisk and Eli Lilly. These moves come as NYSE:HIMS trades at $25.65, with the stock up 31.5% over the past 30 days but down 23.2% year to date and 50.1% over the past year. The...

​Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is one of the best fast growing penny stocks to buy right now. On May 7, Lexicon Pharmaceuticals reported Q1 2026 revenue of $21.1 million, a significant increase from $1.3 million in the prior year, driven by $20.0 million in development milestones from its LX9851 partnership with Novo Nordisk. The company […]

The weight loss drug market is on track to reach almost $100 billion.

Amazon Pharmacy is expanding access to Ozempic pills for type 2 diabetes through same day delivery and kiosk pickups across thousands of US locations. The move broadens digital and retail pharmacy channels for Novo Nordisk, alongside existing access programs with Weight Watchers and GoodRx. This development focuses on oral GLP-1 therapies, adding another distribution layer beyond traditional provider and brick and mortar pharmacy routes. Novo Nordisk (CPSE:NOVO B), trading at DKK290.75, is...

Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index and the State Stree

Ozempic and Wegovy demand rose after Novo lowered prices to compete with generics.

The European stock markets were tracking lower, and oil prices were rising Friday following media re

PRTA posted a Q1 profit as a $50M Novo Nordisk milestone payment boosted revenue and improved its 2026 cash outlook.

Novo Nordisk (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy is emerging as the central battleground for investors in the Danish pharmaceutical giant. And both UBS and Citi are highlighting the pill's trajectory as the defining question for the company's medium-term outlook...

Novo's price cuts lifted Wegovy and Ozempic demand while cheaper GLP-1 therapies expanded India's obesity-drug market.

Switzerland’s Sandoz sees Canada and Brazil markets as testing grounds before semaglutide goes off patent in Europe and the U.S. in the 2030s.

Eli Lilly is just wrapping up trials of its retatrutide, but consumers already are flocking to black-market versions. Can Lilly compete with copies of its own drug?

Novo Nordisk’s Wegovy pill is already providing financial fuel in the company’s bid to catch Eli Lilly.

Lexicon Pharmaceuticals (NASDAQ:LXRX) executives highlighted progress across late-stage regulatory programs and efforts to bolster the company’s financial position during the company’s first-quarter 2026 earnings call on May 7. Chief Executive Officer Mike Exton said the company entered 2026 with o

If you are wondering whether Novo Nordisk stock is attractively priced right now, the key is to understand what the recent share price is actually implying about future expectations. The stock last closed at US$45.80, with recent returns of 8.5% over 7 days and 24.1% over 30 days, but a 27.0% decline over 1 year and a 42.7% decline over 3 years. These moves have come alongside ongoing attention on Novo Nordisk's role in pharmaceuticals and biotech, including its position in treatments that...

Novo Nordisk (CPSE:NOVO B) shocked the market with first quarter 2026 results, as its new oral Wegovy weight loss pill quickly surpassed 2 million US prescriptions and prompted a higher full year outlook. See our latest analysis for Novo Nordisk. The strong first quarter has triggered a sharp rebound in sentiment, with a 25.69% 1 month share price return and 8.54% 7 day gain. However, the year to date share price return of 10.52% and 1 year total shareholder return of 27.91% still point to a...

Novo now expects profit and sales declines of up to 12% this year, better than its earlier 13% forecast.

Eli Lilly has a lofty valuation thanks to its strong GLP-1 growth, but don't count out these two competitors.

Amazon will offer same-day delivery for Novo Nordisk's Ozempic pill.

Novo partnership deepens Amazon healthcare ambitions

Find insight on Amazon Pharmacy, Sanofi, Sunway Health and more in the latest Market Talks covering the health care sector.

Customers with a prescription can pick up the diabetes pill at select One Medical kiosks or have it delivered the same day for $149 a month

LONDON/COPENHAGEN, May 7 (Reuters) - Early data from weight-loss pills are lifting shares in Novo Nordisk and Eli Lilly as investors bet that easier-to-take drugs could expand the market to millions more patients and help counter pricing pressure. Denmark's Novo, ‌which has struggled to keep pace with U.